Skip to main content

Engineering antibody-based molecules for HIV treatment and cure.

Publication ,  Journal Article
Tuyishime, M; Ferrari, G
Published in: Curr Opin HIV AIDS
September 2020

PURPOSE OF REVIEW: Immunotherapy strategies alternative to current antiretroviral therapies will need to address viral diversity while increasing the immune system's ability to efficiently target the latent virus reservoir. Antibody-based molecules can be designed based on broadly neutralizing and non-neutralizing antibodies that target free virions and infected cells. These multispecific molecules, either by IgG-like or non-IgG-like in structure, aim to target several independent HIV-1 epitopes and/or engage effector cells to eliminate the replicating virus and infected cells. This detailed review is intended to stimulate discussion on future requirements for novel immunotherapeutic molecules. RECENT FINDINGS: Bispecific and trispecific antibodies are engineered as a single molecules to target two or more independent epitopes on the HIV-1 envelope (Env). These antibody-based molecules have increased avidity for Env, leading to improved neutralization potency and breadth compared with single parental antibodies. Furthermore, bispecific and trispecific antibodies that engage cellular receptors with one arm of the molecule help concentrate inhibitory molecules to the sites of potential infection and facilitate engagement of immune effector cells and Env-expressing target cells for their elimination. SUMMARY: Recently engineered antibody-based molecules of different sizes and structures show promise in vitro or in vivo and are encouraging candidates for HIV treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin HIV AIDS

DOI

EISSN

1746-6318

Publication Date

September 2020

Volume

15

Issue

5

Start / End Page

290 / 299

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Virology
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Epitopes
  • Antibodies, Neutralizing
  • 4202 Epidemiology
  • 3207 Medical microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tuyishime, M., & Ferrari, G. (2020). Engineering antibody-based molecules for HIV treatment and cure. Curr Opin HIV AIDS, 15(5), 290–299. https://doi.org/10.1097/COH.0000000000000640
Tuyishime, Marina, and Guido Ferrari. “Engineering antibody-based molecules for HIV treatment and cure.Curr Opin HIV AIDS 15, no. 5 (September 2020): 290–99. https://doi.org/10.1097/COH.0000000000000640.
Tuyishime M, Ferrari G. Engineering antibody-based molecules for HIV treatment and cure. Curr Opin HIV AIDS. 2020 Sep;15(5):290–9.
Tuyishime, Marina, and Guido Ferrari. “Engineering antibody-based molecules for HIV treatment and cure.Curr Opin HIV AIDS, vol. 15, no. 5, Sept. 2020, pp. 290–99. Pubmed, doi:10.1097/COH.0000000000000640.
Tuyishime M, Ferrari G. Engineering antibody-based molecules for HIV treatment and cure. Curr Opin HIV AIDS. 2020 Sep;15(5):290–299.

Published In

Curr Opin HIV AIDS

DOI

EISSN

1746-6318

Publication Date

September 2020

Volume

15

Issue

5

Start / End Page

290 / 299

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Virology
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Epitopes
  • Antibodies, Neutralizing
  • 4202 Epidemiology
  • 3207 Medical microbiology